These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1296 related articles for article (PubMed ID: 22931450)

  • 1. Nanotechnology in therapeutics: a focus on nanoparticles as a drug delivery system.
    Bamrungsap S; Zhao Z; Chen T; Wang L; Li C; Fu T; Tan W
    Nanomedicine (Lond); 2012 Aug; 7(8):1253-71. PubMed ID: 22931450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymeric particulate technologies for oral drug delivery and targeting: a pathophysiological perspective.
    Hunter AC; Elsom J; Wibroe PP; Moghimi SM
    Nanomedicine; 2012 Sep; 8 Suppl 1():S5-20. PubMed ID: 22846372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanocarriers for treatment of ocular neovascularization in the back of the eye: new vehicles for ophthalmic drug delivery.
    Shen HH; Chan EC; Lee JH; Bee YS; Lin TW; Dusting GJ; Liu GS
    Nanomedicine (Lond); 2015; 10(13):2093-107. PubMed ID: 26096379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanocarriers for oral drug delivery.
    Zhang L; Wang S; Zhang M; Sun J
    J Drug Target; 2013 Jul; 21(6):515-27. PubMed ID: 23621127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanomedicine opportunities for cardiovascular disease with perfluorocarbon nanoparticles.
    Lanza GM; Winter PM; Caruthers SD; Hughes MS; Cyrus T; Marsh JN; Neubauer AM; Partlow KC; Wickline SA
    Nanomedicine (Lond); 2006 Oct; 1(3):321-9. PubMed ID: 17716162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of nanotechnology in developing new therapies for diseases of the nervous system.
    Jain KK
    Nanomedicine (Lond); 2006 Jun; 1(1):9-12. PubMed ID: 17716203
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmaceutical development and regulatory considerations for nanoparticles and nanoparticulate drug delivery systems.
    Narang AS; Chang RK; Hussain MA
    J Pharm Sci; 2013 Nov; 102(11):3867-82. PubMed ID: 24037829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent Developments in the Application of Polymeric Nanoparticles as Drug Carriers.
    Moritz M; Geszke-Moritz M
    Adv Clin Exp Med; 2015; 24(5):749-58. PubMed ID: 26768624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanoparticles in drug delivery: past, present and future.
    Couvreur P
    Adv Drug Deliv Rev; 2013 Jan; 65(1):21-3. PubMed ID: 22580334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Designing drug-delivery systems for the nervous system using nanotechnology: opportunities and challenges.
    Liu-Snyder P; Webster TJ
    Expert Rev Med Devices; 2006 Nov; 3(6):683-7. PubMed ID: 17280531
    [No Abstract]   [Full Text] [Related]  

  • 11. Advances and challenges of nanotechnology-based drug delivery systems.
    Jiang W; Kim BY; Rutka JT; Chan WC
    Expert Opin Drug Deliv; 2007 Nov; 4(6):621-33. PubMed ID: 17970665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting of injectable drug nanocrystals.
    Fuhrmann K; Gauthier MA; Leroux JC
    Mol Pharm; 2014 Jun; 11(6):1762-71. PubMed ID: 24766270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug delivery systems: entering the mainstream.
    Allen TM; Cullis PR
    Science; 2004 Mar; 303(5665):1818-22. PubMed ID: 15031496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Micro- and nanoparticles--medical applications.
    Jătariu A; Peptu C; Popa M; Indrei A
    Rev Med Chir Soc Med Nat Iasi; 2009; 113(4):1160-9. PubMed ID: 20191893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Has nanotechnology led to improved therapeutic outcomes?
    Bosselmann S; Williams RO
    Drug Dev Ind Pharm; 2012 Feb; 38(2):158-70. PubMed ID: 22191583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanotechnology controlled drug delivery for treating bone diseases.
    Yang L; Webster TJ
    Expert Opin Drug Deliv; 2009 Aug; 6(8):851-64. PubMed ID: 19637973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biopharmaceutical parameters to consider in order to alter the fate of nanocarriers after oral delivery.
    Roger E; Lagarce F; Garcion E; Benoit JP
    Nanomedicine (Lond); 2010 Feb; 5(2):287-306. PubMed ID: 20148639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanocarriers.
    Torchilin VP
    Pharm Res; 2007 Dec; 24(12):2333-4. PubMed ID: 17934800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent trends of nanomedicinal approaches in clinics.
    Dilnawaz F; Acharya S; Sahoo SK
    Int J Pharm; 2018 Mar; 538(1-2):263-278. PubMed ID: 29339248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanobiotechnology-based strategies for crossing the blood-brain barrier.
    Jain KK
    Nanomedicine (Lond); 2012 Aug; 7(8):1225-33. PubMed ID: 22931448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 65.